Proteomic approach to the study of statin pleiotropy in kidney transplant patients

Pharmacology

Volumn 87, Issue 3-4, 2011, Pages 161-168

  Pérez, Vanessa ^a   Navarro Muñoz, Maribel ^a   Mas, Sebastián ^c   Bayés, Beatriz ^a   Pastor, Mari Cruz ^a   Martínez Cáceres, Eva ^b   Lauzurica, Ricardo ^a   Egido, Jesús ^c   Romero, Ramón ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Bradykinin; Complement factor C4; Kidney transplantation; Magnetic beads; Matrix assisted laser desorption ionization time of flight; Proteomics; Statins

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ATORVASTATIN; AZATHIOPRINE; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT COMPONENT C4; CREATININE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMA PROTEIN; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; VASCULITIS;

ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; IMMUNOENZYME TECHNIQUES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PROTEOMICS; PYRROLES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952102329     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324311     Document Type: Article

References (42)

1. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G: Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451-457.
2. Scandinavian Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
3. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebocontrolled trial. Lancet 2003; 361: 2024-2031. (Pubitemid 36695044)
4. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-1164. (Pubitemid 32440937)
5. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
7. Massy ZA, Keane WF, Kasiske BL: Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996; 347: 102-103. (Pubitemid 26017860)
8. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109:III39-III43. (Pubitemid 38786442)
9. Wang CY, Liu PY, Liao JK: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
10. Richter R, Schulz-Knappe P, Schrader M, Standker L, Jurgens M, Tammen H, Forssmann WG: Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl 1999; 726: 25-35. (Pubitemid 29187202)
11. Duran MC, Martin-Ventura JL, Mohammed S, Barderas MG, Blanco-Colio LM, Mas S, Moral V, Ortega L, Tunon J, Jensen ON, Vivanco F, Egido J: Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. Eur J Pharmacol 2007; 562: 119-129. (Pubitemid 46466765)
12. Alonso-Orgaz S, Moreno L, Macaya C, Rico L, Mateos-Caceres PJ, Sacristan D, Perez- Vizcaino F, Segura A, Tamargo J, Lopez- Farre A: Proteomic study of plasma from moderate hypercholesterolemic patients. J Proteome Res 2006; 5: 2301-2308. (Pubitemid 44330823)
13. Barderas MG, Tunon J, Darde VM, De la Cuesta F, Jimenez-Nacher JJ, Tarin N, Lopez- Bescos L, Egido J, Vivanco F: Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. Proteomics 2009; 9: 1982-1993.
14. Perez V, Navarro-Munoz M, Bayes B, Lauzurica R, Pastor MC, Troya M, Bonet J, Ibernon M, Navarro M, Serra A, Nunez A, Romero R: Effect of low doses of atorvastatin on the urinary peptide profile of kidney transplant patients. Transplant Proc 2009; 41: 2111-2114.
15. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P: Serum peptide profiling by magnetic particle- assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004; 76: 1560-1570. (Pubitemid 38338398)
16. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J: Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Clin Chem 2005; 51: 973-980. (Pubitemid 40740877)
17. West-Nielsen M, Hogdall EV, Marchiori E, Hogdall CK, Schou C, Heegaard NH: Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem 2005; 77: 5114-5123. (Pubitemid 41140826)
18. Fiedler GM, Baumann S, Leichtle A, Oltmann A, Kase J, Thiery J, Ceglarek U: Stan dardized peptidome profiling of human urine by magnetic bead separation and matrix- assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2007; 53: 421-428. (Pubitemid 46447938)
19. Callesen AK, Christensen R, Madsen JS, Vach W, Zapico E, Cold S, Jorgensen PE, Mogensen O, Kruse TA, Jensen ON: Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 291-300. (Pubitemid 351212854)
20. Sekiyama E MY, Higo D, Nirasawa T, Ikegawa M, et al: Applying magnetic bead separation/ MALDI-TOF mass spectrometry to human tear fluid proteome analysis. J Proteomics Bioinform 2008; 1: 368-373.
21. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
22. Castelli WP: Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124(suppl):S1-S9.
23. Kasiske BL: Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant 2005; 5: 1576.
24. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F: Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010; 105: 288-292.
25. Masterson R, Hewitson T, Leikis M, Walker R, Cohney S, Becker G: Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 2005; 80: 332-338. (Pubitemid 41130874)
26. Fellström B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C: No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clin Transplant 2006; 20: 732-739. (Pubitemid 44712274)
27. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269. (Pubitemid 32055234)
28. Agarwal R: Effects of statins on renal function. Am J Cardiol 2006; 97: 748-755. (Pubitemid 43255052)
29. Davidson MH: Rosuvastatin safety: Lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 2004; 3: 547-557. (Pubitemid 39530208)
30. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on c-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70. (Pubitemid 32606333)
31. Nawawi H, Osman NS, Yusoff K, Khalid BA: Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 2003; 35: 479-485. (Pubitemid 37204564)
32. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ: Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002; 165: 361-366. (Pubitemid 35333363)
33. Ozaki K, Kubo T, Imaki R, Shinagawa H, Fukaya H, Ohtaki K, Ozaki S, Izumi T, Aizawa Y: The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. J Atheroscler Thromb 2006; 13: 216-219.
34. Singh U, Devaraj S, Jialal I, Siegel D: Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008; 102: 321-325.
35. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080. (Pubitemid 38541684)
36. Horiuchi Y, Hirayama S, Soda S, Seino U, Kon M, Ueno T, Idei M, Hanyu O, Tsuda T, Ohmura H, Miida T: Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. J Atheroscler Thromb 2010; 17: 722-729.
37. Campbell DJ, Kladis A, Zhang Y, Jenkins AJ, Prior DL, Yii M, Kenny JF, Black MJ, Kelly DJ: Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 2010; 53: 779-785.
38. Tschope C, Schultheiss HP, Walther T: Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 2002; 39: 478-487. (Pubitemid 34252382)
39. Cavusoglu E, Eng C, Chopra V, Ruwende C, Yanamadala S, Clark LT, Pinsky DJ, Marmur JD: Usefulness of the serum complement component C4 as a predictor of stroke in patients with known or suspected coronary artery disease referred for coronary angiography. Am J Cardiol 2007; 100: 164-168. (Pubitemid 47041975)
40. Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, Wagner O, Huber K, Minar E, Wojta J, Schillinger M: Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26: 2294-2299. (Pubitemid 41541394)
41. Szeplaki G, Prohaszka Z, Duba J, Rugonfalvi- Kiss S, Karadi I, Kokai M, Kramer J, Fust G, Kleiber M, Romics L, Varga L: Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004; 177: 383-389. (Pubitemid 39505272)
42. Sampietro T, Bigazzi F, Rossi G, Dal Pino B, Puntoni MR, Sbrana F, Chella E, Bionda A: Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy. J Intern Med 2005; 257: 523-530. (Pubitemid 40776512)